FINWIRES · TerminalLIVE
FINWIRES

$MRNA

32 stories mentioning MRNA

Every FINWIRES story that references MRNA, newest first.

Commodities

Exchange-Traded Funds Higher, Equity Futures Mixed Amid Continued Earnings Results

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively traded Invesco QQQ Trust (QQQ) gained 0.1% in Friday's premarket activity, as earnings reports continued to pour in.US stock futures were mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures gaining 0.3%, and Nasdaq futures slipping by 0.2% before the start of regular trading.The S&P Global US manufacturing purchasing managers index for April will be released at 9:45 am ET, followed by the ISM Manufacturing Index for April at 10 am ET.The weekly Baker Hughes domestic oil-and-gas rig count posts at 1 pm ET.In premarket action, bitcoin was up by 1.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.3% higher, Ether ETF (EETH) advanced 2.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.6%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.4% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat. The iShares US Consumer Staples ETF (IYK) was also flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.1%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.5% higher.Estee Lauder (EL) shares were up more than 11% pre-bell after the company reported higher fiscal Q3 earnings and said it expects to eliminate between 9,000 and 10,000 positions as part of a revised profit recovery program.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.4%, the Vanguard Health Care Index Fund (VHT) was up 1.2%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was flat.Moderna (MRNA) stock was up more than 3% premarket after the company reported a narrower-than-expected net loss and higher revenue.EnergyThe iShares US Energy ETF (IYE) was down 0.1%, while the State Street Energy Select Sector SPDR ETF (XLE) was 0.4% lower.Imperial Oil (IMO) stock was down more than 2% before Friday's opening bell after the company reported lower Q1 net income and revenue.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1.3%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.1% lower.Aon (AON) shares were up 3% pre-bell after the company reported higher Q1 adjusted earnings and revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.4%, while the Vanguard Industrials Index Fund (VIS) gained 0.4% and the iShares US Industrials ETF (IYJ) was inactive.Gates Industrial (GTES) stock was up more than 3% before the opening bell after Timken (TKR) agreed to sell the assets of its belts business to Gates.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.3%, and the iShares US Technology ETF (IYW) was 0.6% higher, while the iShares Expanded Tech Sector ETF (IGM) was down 0.03%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined by 0.4%, while the iShares Semiconductor ETF (SOXX) fell by 0.8%.Apple (AAPL) shares were up about 3% in premarket activity after the iPhone maker's fiscal Q2 results topped market estimates.CommoditiesFront-month US West Texas Intermediate crude oil fell by 2.6% to $102.31 per barrel on the New York Mercantile Exchange. Natural gas gained by 0.3% to $2.78 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased by 2%, while the United States Natural Gas Fund (UNG) was 0.8% higher.Gold futures for May were down by 0.5% to $4,607.80 an ounce on the Comex. Silver futures added 1.5% to $75.31 an ounce. SPDR Gold Shares (GLD) was 0.5% lower, and the iShares Silver Trust (SLV) gained by 0.8%.

Dow JonesNasdaq CompositeS&P 500$AAPL$AON$BETH$BITO$EEM$EETH$EL$EXI$FAS$FAZ$GLD$GTES$IBB$IGM$IGV$IMO$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MRNA$PMR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Health Care Stocks Advance Pre-Bell Friday

Health care stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.2%.Novo Nordisk (NVO) shares were up more than 2% after the company said it has rebranded its oral semaglutide medication for type 2 diabetes, formerly known as Rybelsus, as Ozempic.Veeva Systems (VEEV) is set to join the S&P 500 on May 7, to replace Coterra Energy (CTRA), S&P Dow Jones Indices said. Shares of Veeva Systems were up more than 11% premarket.Moderna (MRNA) stock was up more than 2% after the company reported a narrower-than-expected Q1 net loss.

$CTRA$IBB$MRNA$NVO$VEEV$XLV
Research

Research Alert: Mrna Q1 Beats Estimates Despite Litigation Charge, Pipeline Advances

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Moderna's Q1 2026 revenue tripled to $389M, beating the consensus view by $154M, due to COVID-19 vaccine deliveries under international partnerships. Net loss widened to $(3.40) per share from $(2.52) prior year, though beat consensus by $0.48, primarily due to a $0.9B litigation settlement charge that added $(2.22) to EPS. We view the strong revenue performance and international expansion as positive, with international markets contributing 80% of revenue and completion of the first U.K. partnership shipment. Management maintained the 2026 guidance for up to 10% revenue growth with 50/50 U.S./international split. We believe regulatory milestones including European approval of combination vaccines and pipeline advancement demonstrate execution on its diversification strategy. Key upcoming catalysts include Phase 3 melanoma results, norovirus efficacy data, and the August PDUFA date for seasonal flu vaccine mRNA-1010.

$MRNA
US Markets

Stocks Mostly Up Pre-Bell as Investors Await More Corporate Earnings

The benchmark US stock measures were mostly pointing higher before the open Friday as investors await the week's final round of corporate earnings and track ongoing Middle East tensions, with no apparent signs of progress toward a peace deal between Washington and Tehran.The S&P 500 rose 0.1% and the Dow Jones Industrial Average added 0.2% in premarket activity, while the Nasdaq was off 0.1%. The indexes finished Thursday's trading session in the green, with the S&P 500 and Nasdaq logging new closing highs.Oil giants Exxon Mobil (XOM) and Chevron (CVX) are scheduled to release their latest quarterly results before the bell, along with Colgate-Palmolive (CL), Estee Lauder (EL), Moderna (MRNA), Magna International (MGA) and Newell Brands (NWL).Shares of Apple (AAPL) advanced 2.8% pre-bell as the iPhone maker's fiscal second-quarter results topped market estimates. Reddit (RDDT) climbed 16% after the social media platform recorded better-than-expected first-quarter results and issued an upbeat revenue outlook for the ongoing three-month period at the midpoint. Nvidia (NVDA) rebounded 0.4% following a 4.6% decline at the close of Thursday.President Donald Trump told reporters at the White House on Thursday that the US will maintain its naval blockade of Iranian ports, according to Bloomberg News. "Their economy is crashing, the blockade is incredible," Trump reportedly said. "So we'll see how long they hold out."Iran's new supreme leader, Mojtaba Khamenei, reportedly said Thursday that Iran will defend its nuclear and missile capabilities.West Texas Intermediate crude oil inclined 0.3% to $105.43 a barrel before the opening bell, while Brent increased 0.9% to $111.37.US economic growth fell short of Wall Street's expectations in the first quarter as spending slowed amid inflationary pressures, government data showed Thursday.Separate official data showed that inflation, as measured by the personal consumption expenditure price index, accelerated in March to the fastest pace since mid-2022 as the Middle East conflict sent energy prices soaring.Treasury yields were down in premarket action, with the two-year rate nudging 0.1 basis point lower to 3.88% and the 10-year rate decreasing 0.8 basis point to 4.38%.Friday's economic calendar has the final Purchasing Managers' manufacturing index for April at 9:45 am ET, followed by the Institute for Supply Management's manufacturing index for the same month at 10 am. The weekly Baker Hughes oil-and-gas rig count posts at 1 pm.Gold fell 1.1% to $4,578 per troy ounce, while bitcoin rose 1.1% to $77,248.

Dow JonesNasdaq CompositeS&P 500$AAPL$CL$CVX$EL$MGA$MRNA$NVDA$NWL$RDDT$XOM
Wire

Moderna Q1 Loss Widens, Revenue Rises; Reiterates 2026 Revenue Outlook

Moderna (MRNA) reported a Q1 net loss Friday of $3.40 per diluted share, widening from a loss of $2.52 a year earlier.Analysts polled by FactSet expected a loss of $4.45.Revenue for the quarter ended March 31 was $389 million, up from $108 million a year earlier.Analysts surveyed by FactSet expected $236.4 million.For 2026, the company said it continues to target 10% revenue growth year over year. Analysts polled by FactSet expect $2.10 billion.Shares of the company were over 8% higher in Friday premarket activity.Price: $49.71, Change: $+3.85, Percent Change: +8.38%

$MRNA
Wire

Salesforce Says Moderna Selects Agentforce Platform to Consolidate Commercial Operations

Salesforce (CRM) said Tuesday that Moderna (MRNA) has selected its Agentforce Life Sciences platform to consolidate commercial operations worldwide.The platform will combine data, artificial intelligence, and customer interactions across multiple regions into a single system, Salesforce said.The agreement allows the drugmaker to integrate information from different networks to generate real-time insights for cross-channel promotional campaigns, Salesforce said.The software's open architecture will connect various operations to support Moderna in scaling without vendor restrictions, the company added.Price: $182.49, Change: $+2.31, Percent Change: +1.28%

$CRM$MRNA
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks fell late Monday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) losing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.4%.In corporate news, Eli Lilly (LLY) agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and subsequent payouts based on the achievement of clinical and regulatory milestones. Lilly shares fell 1.6%.HCA Healthcare (HCA) may face pressure through at least H1 as investors rotate toward managed care, although better trends in March and in-line exchange dynamics support the longer-term outlook, RBC Capital Markets said. HCA Healthcare shares rose 3.2%.Organon (OGN) shares jumped 17% after the company agreed to be acquired by India's Sun Pharmaceutical Industries for $14 a share in cash, valuing the company at $11.75 billion.Moderna (MRNA) is facing a patent infringement lawsuit from CureVac, which alleged that Moderna's COVID-19 vaccine Spikevax used its proprietary mRNA technology without authorization, Reuters reported Saturday. Moderna shares fell 4.7%.

$HCA$LLY$MRNA$OGN
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks were lower Monday afternoon with the NYSE Health Care Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.2%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Eli Lilly (LLY) said Monday it has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and subsequent payouts based on the achievement of clinical and regulatory milestones, the company said. Lilly shares were down 0.5%.Organon (OGN) shares jumped 17% after the company agreed to be acquired by India's Sun Pharmaceutical Industries $14 a share in cash, valuing the company at $11.75 billion.Moderna (MRNA) is facing a patent infringement lawsuit from CureVac, which alleged that Moderna's COVID-19 vaccine Spikevax used its proprietary mRNA technology without authorization, Reuters reported Saturday. Moderna shares were falling 3.3%.Catalyst Pharmaceuticals (CPRX) is being considered as a potential acquisition by Italy's Angelini Pharma, Bloomberg reported. Catalyst shares rose past 6%.

$CPRX$LLY$MRNA$OGN
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Extended US-Iran Ceasefire

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6%, and the actively traded Invesco QQQ Trust (QQQ) was 0.7% higher in Wednesday's premarket activity as US President Donald Trump extended the ceasefire with Iran.US stock futures were also higher, with S&P 500 Index futures up 0.6%, Dow Jones Industrial Average futures advancing 0.5%, and Nasdaq futures gaining 0.7% before the start of regular trading.US mortgage applications rose 7.9% in the week ended April 17 as lower borrowing costs drove gains in both refinancing and purchase activity, Mortgage Bankers Association data showed Wednesday.The Atlanta Fed Business Inflation Expectations survey for April is scheduled for release at 10 am ET, followed by the weekly EIA domestic petroleum inventories report at 10:30 am ET.In premarket activity, bitcoin was up by 4.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 4.5% higher, Ether ETF (EETH) advanced 4.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.8%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 1%, while the Vanguard Industrials Index Fund (VIS) was up 2% and the iShares US Industrials ETF (IYJ) was inactive.Target Hospitality (TH) stock was down more than 9% before the opening bell, a day after the company said its selling shareholders priced a secondary offering of 7 million shares at $14 apiece for about $98 million in gross proceeds.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 1%, and the iShares US Technology ETF (IYW) was 1.2% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 1.8%, while the iShares Semiconductor ETF (SOXX) rose by 1.5%.TE Connectivity (TEL) shares were down more than 5% in Wednesday's premarket activity despite the company delivering strong fiscal Q2 results that beat estimates after CEO Terrence Curtin told Reuters that persistent Middle East conflict could force price hikes to offset rising material costs and supply chain disruptions.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, the Vanguard Health Care Index Fund (VHT) was up 0.4%, while the iShares US Healthcare ETF (IYH) was flat. The iShares Biotechnology ETF (IBB) was up 0.7%.Moderna (MRNA) stock was down more than 1% premarket, a day after the company said it administered the initial doses to participants in the US and the UK for a phase 3 clinical trial evaluating its experimental mRNA-1018 pandemic flu vaccine.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1.1%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.8% lower.Capital One Financial (COF) shares were down more than 1% pre-bell after the company overnight reported Q1 results that fell short of analyst expectations.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was 0.4% higher. The iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.7%. The VanEck Retail ETF (RTH) was down 0.1%, while the State Street SPDR S&P Retail ETF (XRT) increased 0.6%.Alibaba Group (BABA) shares were up more than 1% pre-bell after The Information reported the company and Tencent are in talks to invest in DeepSeek, which is seeking funding at a valuation of over $20 billion.EnergyThe iShares US Energy ETF (IYE) was flat, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 0.1%.NexGen Energy (NXE) stock was up more than 1% before the opening bell after the company said it completed its 2026 winter drill program at the Patterson Corridor East discovery, extending the vertical extent of the high-grade uranium zone by 33% to 550 meters.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.4% to $89.29 per barrel on the New York Mercantile Exchange. Natural gas declined by 0.8% to $2.67 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 0.9%, while the United States Natural Gas Fund (UNG) was 0.4% higher.Gold futures for May were down by 0.4% at $4,812.10 an ounce on the Comex. Silver futures retreated by 1.1% to $79.73 an ounce. SPDR Gold Shares (GLD) was 0.4% lower, and the iShares Silver Trust (SLV) fell by 0.7%.

Dow JonesNasdaq CompositeS&P 500$BABA$BETH$BITO$COF$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MRNA$NXE$PMR$QQQ$RTH$SLV$SOXX$SPY$TEL$TH$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Wire

Moderna Says European Commission Grants Marketing Authorization for mCombriax Vaccine for Influenza, COVID-19

Moderna (MRNA) said Tuesday the European Commission has granted marketing authorization for its mCombriax vaccine for the prevention of influenza and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older.The marketing authorization is valid in all 27 European Union member states, as well as Iceland, Liechtenstein and Norway, Moderna said.The Commission's authorization is based on the results from the phase 3 clinical study evaluating the safety, reactogenicity, and immunogenicity of mCombriax in two independent age groups of about 4,000 adults each, Moderna said.Price: $54.02, Change: $-0.57, Percent Change: -1.04%

$MRNA
Wire

Moderna's Investigational Cancer Therapy Shows Promising Early Trial Results

Moderna (MRNA) said Friday that early clinical trial data for its cancer therapy mRNA-4359 showed an 83% overall response rate, building confidence in the treatment's potential.The therapy is being evaluated in combination with pembrolizumab, an immunotherapy drug for various types of cancer, as a first-line treatment for patients with advanced or metastatic melanoma.The company said the US Food and Drug Administration has granted Fast Track designation to the combination for certain patients with advanced melanoma, which could speed up its development and regulatory review.Moderna will present results from the Phase 1/2 study at the American Association for Cancer Research annual meeting, scheduled for April 17 to April 22.Price: $54.50, Change: $-0.18, Percent Change: -0.33%

$MRNA
Wire

Goldman Sachs Adjusts Moderna Price Target to $43 From $41, Maintains Neutral Rating

Moderna (MRNA) has an average rating of Hold and mean price target of $45.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $55.38, Change: $+0.70, Percent Change: +1.28%

$MRNA

Showing 21-32 of 32